Anti Cd 20 Ocrevus denied as not FDA-approved for this use by Cigna?

Cigna's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Issue a "Not FDA-Approved" Denial for Ocrelizumab

Ocrelizumab (Ocrevus) holds FDA approval for specific forms of multiple sclerosis. A "not FDA-approved" denial from Cigna almost always means one of two things: the claim was coded in a way that suggests an off-label use, or an administrative error caused the system to flag the drug against the wrong indication. It does not necessarily mean the treatment is inappropriate for your situation.

## Why This Denial Is Appealable

FDA approval status is a factual, verifiable matter. If your prescriber is using ocrelizumab for an indication that the FDA has approved, the denial is incorrect on its face and must be corrected on appeal. You are entitled to a full written explanation of exactly which indication Cigna claims is unapproved. If the actual prescribed indication is listed in the FDA-approved labeling, the appeal is straightforward.

## Your Federal Appeal Rights

• Internal appeal: Under ACA §2719 and ERISA §503, you have the right to a full-and-fair internal review. Submit your internal appeal within the timeframe stated in your denial letter (commonly 180 days for ERISA plans).
• External review: If the internal appeal is denied, you may escalate to an independent external reviewer under ACA §2719. This window is generally open for approximately four months after exhausting internal remedies.
• Expedited review: If your condition is urgent or you are mid-treatment, request expedited review; decisions are typically required within 72 hours.

## Documentation to Gather

1. Prescriber letter confirming the exact indication being treated and citing the FDA-approved labeling. 2. Diagnosis records — neurologist notes, MRI reports, and any diagnostic workup confirming the MS diagnosis and classification. 3. FDA prescribing information — print the current approved label and highlight the indication that applies to your case. 4. Prior treatment history — a dated summary of any previous disease-modifying therapies tried, with outcomes. 5. Cigna's written denial — obtain the specific policy language or coverage determination Cigna relied upon.

## Criteria-Mapping Approach

Create a two-column table. In the left column, copy each coverage requirement from Cigna's policy exactly as written. In the right column, cite the specific chart note, lab result, or clinical record that satisfies each requirement. For the FDA-approval question specifically, place the exact indication language from the FDA label in the left column and the prescriber's documented diagnosis in the right column. This side-by-side mapping removes ambiguity and forces the reviewer to engage with the evidence directly.

## Next Step

Request Cigna's complete coverage policy for ocrelizumab in writing before drafting your appeal. Confirm the precise indication documented in your chart matches the language in the current FDA-approved prescribing information. A clear mismatch between the denial rationale and the documented facts is often enough to overturn this type of denial at the internal review stage.